Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sofe-M

Phase 1

Sofe-M is one of 9 therapeutic programs targeting Ovarian Neoplasms. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

8

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ovarian NeoplasmsRecruiting

Ovarian NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Ovarian Neoplasms

#DrugCompanyPhaseTrials

Avastin

Keytruda

Trodelvy

Paraplatin

Rescue

Mocertatug Rezetecan

Zejula

GGlaxo Dba Glaxosmithkline

Sporanox

SSebela Pharmaceuticals Development LLC

Sofe-M

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Ovarian Neoplasms

NCT06400472

Clinical

Trials by Indication[1]

Ovarian Neoplasms1 trial

A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06400472·575 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sofe-M. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sofe-M. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Eli Lilly

Related News